Podcasts about PAC

A coaching client hit "apply filter" and watched 3,800 qualified ASINs appear on screen. His shoulders dropped. He breathed a sigh of relief. He finally had runway. Here's the thing, no one sold him that list. He built it. This episode breaks down the exact approach: how many hours, how many weeks, what filters matter, and why your own database is the only competitive moat that actually lasts.   Special guest at the conclusion of today's show, Jeff Schick of JeffSchick.com answers the question: "What is a Section 3 Amazon seller audit, and is Amazon actually punishing sellers?" Use coupon code "MISTAKE" to get your first month of services for only $1 with Jeff and his team!   Watch this episode on our YouTube channel here: https://youtu.be/-GxuT5Vaxvo   Show note LINKS:  SilentJim.com/arb - discount on ArbSource SilentJim.com/oaleads - discount on Nepeto SilentJim.com/fbaleads - FBA LeadsList   3PMercury.com/friends  - The best price you'll ever see on 3PMercury software! Give us a call - we'd love to talk about how it works! SilentJim.com/bookacall has contact info.   ProvenAmazonCourse.com - The comprehensive course that contains ALL our Amazon training modules, recorded events and a steady stream of latest cutting edge training including of course the most popular starting point, the REPLENS selling model. The PAC is updated free for life!   My Silent Team Facebook group. 100% FREE! Facebook.com/groups/mysilentteam - Join 82,000 + Facebook members from around the world who are using the internet creatively every day to launch and grow multiple income streams through our exciting PROVEN strategies! There's no support community like this one anywhere else in the world!   SilentJim.com/bookacall - Schedule a FREE, customized and insightful consultation with my team or me (Jim) to discuss your e-commerce goals and options.                    

The Federal Reserve is set to cut interest rates to shore up a shaky job market. Another federal judge has just ruled on releasing records relating to Jeffrey Epstein's 2019 sex trafficking case. There are more instances of US strikes on alleged drug boats that have initially left survivors. A pro-AI super PAC is launching its first candidate ads. Plus, why this year's Nobel Peace Prize winner wasn't there to collect the award. Learn more about your ad choices. Visit podcastchoices.com/adchoices

"What's good for the heart is good for the brain."  Can better cholesterol management in midlife actually lower your patient's risk of Alzheimer's disease? In this episode, I'm joined by returning guest Josh Wageman, PhD, PA-C, a clinical lipid specialist who studied cholesterol disturbances in Alzheimer's disease.  Together, we unpack how cholesterol, APOB, APOE4, insulin resistance, and statins intersect with Alzheimer's disease and cognitive decline, and what clinicians can do now to protect brain health long before symptoms appear. Plus, a peek at emerging therapies (including GLP-1 receptor agonists and lipid-centric approaches) and how a metabolic lens is reshaping future Alzheimer's treatment.Resources Mentioned:Josh's New Book117 | What's the Best Diet to Lower Cholesterol?111 | HDL = Good, LDL = Bad? It's Not That Simple.80 | The MIND Diet: What To Eat For Brain HealthAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week. Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer.

Wouldn't it be great if someone would just SHOW YOU THE STEPS TO SUCCESS? We'd all like to think that if someone would just lay it all out in clearly defined steps then we could push the right buttons, use the right tools and follow the plan to building a great business online (just like building a lego set, right?)   If you've not figured it out yet, building a business is NOT like building a LEGO set! It's more like taking a leadership journey with surprises around each new bend in the path! So what's the plan you should follow?   The people you choose to surround yourself with, the mindset you bring daily and the small disciplines that you establish are bigger factors than you might realize. I know of very few exceptions of successful students in our community who don't understand these dynamics.   We pride ourselves on giving you the step by step blueprint for building a great business on Amazon, but COMMUNITY, MINDSET and DISCIPLINE play a bigger role than STRATEGY! Let's talk about it.   Watch this episode on our YouTube channel here: https://youtu.be/f4FGIcuCeqU   Show note LINKS:    SilentJim.com/bookacall - Schedule a FREE, customized and insightful consultation with my team or me (Jim) to discuss your e-commerce goals and options.   ProvenAmazonCourse.com - The comprehensive course that contains ALL our Amazon training modules, recorded events and a steady stream of the latest cutting-edge training, including, of course, the most popular starting point, the REPLENS selling model. The PAC is updated free for life!   Facebook.com/groups/mysilentteam - My Silent Team Facebook group. 100% FREE! Join 82,000+ Facebook members from around the world who use the internet creatively every day to launch and grow multiple income streams through our exciting, proven strategies! There's no support community like this one anywhere else in the world!   SilentJim.com/thesystem  - (aka as 3P Mercury) - The complete workflow software we created on our team. "The System" automates your Amazon reselling/wholesale business the same way Khang (the creator) automated his $3million reselling business and made it HANDS FREE!

Do fim do xogunato à rendição na Segunda Guerra Mundial, o Império do Japão passou por uma transformação profunda que o levou de um país isolado para uma potência industrial, militar e imperialista. A Restauração Meiji desencadeou um processo acelerado de modernização que reorganizou o Estado, impulsionou a industrialização e fortaleceu as Forças Armadas sob a lógica de que apenas um país forte poderia evitar a submissão às potências ocidentais. Esse impulso expansionista ganhou forma em sucessivas guerras — contra a China, a Rússia e em campanhas pela Ásia-Pacífico — que consolidaram o Japão como ator central nas disputas imperiais do início do século XX. Sob crescente nacionalismo, militarismo e autoritarismo, o regime conduziu a população a uma mobilização total para a guerra e foi responsável por graves atrocidades. A derrota em 1945 representou o colapso do império, a ocupação aliada e a construção de um novo Japão sob bases constitucionais democráticas. Convidamos Jojo Netto para analisar o surgimento, a expansão e o declínio do Império Japonês, discutindo as tensões internas, os projetos nacionais e os impactos duradouros desse período na história contemporânea do Japão.Adquira o curso História: da pesquisa à escrita por apenas R$ 49,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso A Operação Historiográfica para Michel de Certeau por apenas R$ 24,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Adquira o curso O ofício do historiador para Marc Bloch por apenas R$ 29,90 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠CLICANDO AQUI⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Colabore com nosso trabalho em ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠apoia.se/obrigahistoria⁠⁠⁠Presente de fim de ano é com a INSIDER. Use o cupom HISTORIAFM ou o link à seguir para estar apto a conseguir até 30% de desconto + 20% de cashback: https://creators.insiderstore.com.br/HISTORIAFM #insiderstore

QD300: Flare or Beware (featuring Lindsay Tom, PA-C and Phong Nguyen, MD) QD301: CAR-T Cell Therapy for Lupus  (featuring Philip Mease, MD and Cayla Alexander, DNP) QD302: Unweanable PMR  (featuring Jack Cush, MD, and Leilani Law, APN) QD303: Weakness with Fibromyalgia  (featuring Jack Cush, MD, and Leilani Law, APN)

Sponsored by thegalindocollective.com, BHIhats.com, Austin.Patchmaster.com  - The Texas State Bobcats are heading back to DFW for the postseason to take on the Rice Owls in the Armed Forces Bowl on Jan. 2. Plus, quarterback Brad Jackson announced on Friday night that he would return for the Bobcats debut season in the Pac-12 in 2026, along with his two favorite targets, Beau Sparks and Chris Dawn Jr. Keff Ciardello is here to wrap up the wild news week for Texas State football. Check out the WNOGB YouTube Channel!

Send us a textThe mixtapes raised a generation, but the documentary forces a reckoning. We pull back the curtain on Sean Combs' climb from Uptown intern to Bad Boy mogul and walk through the cultural milestones that made the 90s feel invincible—then we test those memories against the stories many never wanted to tell. From Jodeci's leather-and-Timb boots to Mary J's raw soul, from Craig Mack's spark to Biggie's reign, we trace how a glossy East Coast sound took over radio while rivalries with Death Row and the Source Awards lit a fuse the industry couldn't control.The conversation gets real when the music stops and the power starts. We revisit the Quad Studio shooting, the tensions around Pac and Biggie, and the Vegas night that still haunts hip-hop's timeline. Alongside the headlines are the quieter mechanics: contracts that promised fame but not wealth, gatekeeping that rewarded silence, and the uncomfortable calculus of access over ethics. “Making the Band” nostalgia turns into a lesson on control and career stall-outs; claims from collaborators like Little Rod introduce intimate, manipulative receipts that are hard to shake. The documentary doesn't act as judge; it catalogs patterns and asks what we ignore to keep our favorite songs untouched.By the end, we're weighing legal outcomes against moral clarity. Did public campaigns sway the process? How much responsibility lies with the machine around a star—managers, peers, fans—who benefit while looking away? For listeners who lived the era, this is a gut check: can we separate art from artist, or does the backstory change how the music hits? Hit play for a candid, layered walkthrough of The Reckoning, the East–West fault lines, and the costs hiding in fine print. If this era shaped your playlists and your memories, you'll have thoughts—subscribe, share your take, and tell us: what do you believe now that you didn't before?

In this week's episode of All Elite Conversation Club, PWTorch contributors Joel Dehnel and Gregg Kanner cover these topics:(00:00) Introductions(02:24) Netflix purchasing a portion of WBD for $82.7 billion(11:54) Darby Allin injured in Continental Classic match(15:53) Okada beats PAC(23:01) Kyle Fletcher beats Kevin Knight(29:48) Don Callis Family vs. The Elite storyline developing; possible multi-man tag before pay-per-view(34:08) Claudio defeats Jon Moxley in main event(39:56) Women's Tag Tournament Finals: Timeless Love Bombs vs. Babes of Wrath at Winter is Coming(46:28) Eddie Kingston vs. Samoa Joe for world title at Winter is Coming(52:32) Upcoming shows: ROH Final Battle Columbus, Winter is Coming Atlanta/Cardiff, Holiday Bash in Manchester(1:02:50) Dynamite Diamond Ring(1:09:44) Zach's Email and Trivia(1:14:40) Greg struggled with Bobby Eaton (Beautiful Bobby, Midnight Express tag team); needed multiple hints(1:28:36) Sports fan tangentsBecome a supporter of this podcast: https://www.spreaker.com/podcast/pwtorch-dailycast--3276210/support.

Is AI building the future — or inflating the next great tech bubble?This week's episode of Leveraging AI peels back the layers of billion-dollar optimism and uncovers the quiet panic sweeping the AI giants. From OpenAI's internal “Code Red” to Anthropic's cautious warnings, host Isar Meitis walks you through the pivotal shifts shaking the foundation of the AI industry.While tech giants throw trillions into compute power and bold promises, business adoption is… shockingly stagnant. Are we seeing signs of a bubble about to burst — or is the market simply catching its breath before the next leap?If you're a business leader navigating the hype, headlines, and high stakes, this is your briefing.In this session, you'll discover:Why OpenAI froze development and went into Code Red modeHow $8 trillion in projected AI infrastructure is colliding with disappointing ROIThe growing disconnect between enterprise AI adoption and corporate AI spendWhat top CEOs like IBM's Arvind Krishna and Anthropic's Dario Amodei really think about the AI investment surgeA jaw-dropping look at deep AI infrastructure costs and the five-year obsolescence cycleWhy Claude Opus 4.5 is being called the best coding model on the marketThe bold new moves from AWS, including agentic AI factoriesPolitical pressures: PAC wars, employee protests, and the race to regulateAnd what your company should (and shouldn't) do right now to stay aheadAbout Leveraging AI The Ultimate AI Course for Business People: https://multiplai.ai/ai-course/ YouTube Full Episodes: https://www.youtube.com/@Multiplai_AI/ Connect with Isar Meitis: https://www.linkedin.com/in/isarmeitis/ Join our Live Sessions, AI Hangouts and newsletter: https://services.multiplai.ai/events If you've enjoyed or benefited from some of the insights of this episode, leave us a five-star review on your favorite podcast platform, and let us know what you learned, found helpful, or liked most about this show!

Lionel tears down the headlines, exposing the real monsters under the bed. Tonight: We confront George Soros's PAC network systematically installing prosecutors nationwide to reshape criminal justice. Plus, a scathing look at medical recklessness, featuring "gender doctors" improvising life-altering procedures on vulnerable youth and the bizarre $13,750 rib removal surgery driven by the 'Ozempic Body' craze. We tackle the future of AI amid OpenAI's massive copyright suit, Palantir's cynical political reversal toward ICE tracking, and why commercial pilots are concealing dangerous mental health struggles. It's an aggressive, cutting critique of modern culture that tells those with "digital burnout" to "Shut up. Butch up. Grow a pair". Learn more about your ad choices. Visit megaphone.fm/adchoices

On December 9th, the Supreme Court will hear oral arguments in National Republican Senatorial Committee v. FEC, a case challenging federal limits on coordinated party expenditures. Legal expert Steve Roberts of Lex Politica breaks down why this First Amendment case could make hard dollars more relevant than they've been in a generation—and what it means for PAC directors' fundraising strategies. 

Bubba Dub is back with a full-on rollercoaster episode after the Dallas Cowboys fall to the Detroit Lions. Dub breaks down the entire night with humor, frustration, and unfiltered honesty as only he can. In this episode, Bubba dives into:

Michigan State $401M commitment, Pac-12 Commissioner Teresa Gould talks the league's new media rights deal and more.We would love to know what you think of the show and you can let us know on social media @D1ticker.If you are not subscribed to D1.ticker, you can and should subscribe at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.d1ticker.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

In this episode, we sit down with Kristin Burton, MPAS, PA-C—a pulmonary and critical care physician assistant and founder of Millionaires in Medicine. Kristin shares her incredible journey from paying off over $160,000 in student loans in just 16 months to reaching millionaire status by age 31. She explains how financial literacy transformed her life and why it's essential for medical professionals to prioritize it.We also dive into Kristin's career path, from clinical work to adjunct faculty roles, expert witness gigs, and entrepreneurship, offering practical tips on time management, networking, and building wealth without sacrificing your medical career. Plus, Kristin gives us a look at her company's mission to help thousands of clinicians achieve financial freedom.Learn more and access free resources at millionairesinmedicine.com.

Se emite una alerta de ola de calor severa para la mayor parte de Nueva Gales del Sur. Un nuevo ataque de Estados Unidos contra una supuesta narco lancha en el Pacífico oriental, deja cuatro muertos y eleva a 87 el total de fallecidos en operaciones similares. Escucha estas y otras noticias importantes del 28 de noviembre.

John Pollock and Wai Ting review AEW Dynamite with Continental Classic matches including Moxley vs. Castagnoli, Kazuchika Okada vs. PAC, and Fletcher vs. Knight. Plus, a Hardcore Holiday Death Match between The MegaProblems and Timeless Love Bombs.XL: The latest details on TNA's deal with AMC, how Hiroshi Tanahashi's retirement match came to be, New Japan's World Tag League continues, and Nick Khan discusses the Ali Boxing Revival Act.The XL Edition continues at POSTwrestlingCafe.com with News of the Day and Feedback, ad-free and timestamped.The latest on TNA's deal with AMC TNA president Carlos Silva on Ariel Helwani's ShowTanahashi's Final Match: The Final Road by Trish Speirs NJPW World Tag League - Night 10Nick Khan chats about Ali Boxing Revival Act POST Wrestling Café Schedule:Thursday: Rewind-A-Wai - WWF Survivor Series 1991Friday: Rewind-A-SmackDown XLSaturday: TNA Final Resolution with John PollockSunday: UFC 323 with Jack Wannan & Eric Marcotte FREE Shows:Friday: Rewind-A-SmackDownSaturday: Collision Course with Kate from MTL & Wai TingSunday: NXT Deadline with Poisonrana  Photo Courtesy: AEWRewind-A-Dynamite Theme by Jacob ChesnutBluesky: https://bsky.app/profile/postwrestling.comX: http://www.twitter.com/POSTwrestlingInstagram: http://www.instagram.com/POSTwrestlingFacebook: http://www.facebook.com/POSTwrestlingYouTube: http://www.youtube.com/POSTwrestlingSubscribe: https://postwrestling.com/subscribePatreon: http://postwrestlingcafe.comForum: https://forum.postwrestling.comDiscord: https://postwrestling.com/discordOur Sponsors:* Check out Progressive: https://www.progressive.com* Check out Uncommon Goods: https://uncommongoods.com/postwrestlingAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Thirty boxes of handwritten journals. A Bad Boy co-founder who suddenly vanished from the industry. Gang witnesses, investigators, insiders, and a decades-old pattern finally pushed into the light. In today's episode of Hidden Killers, we dig into the most explosive element in the new documentary surrounding Sean “Diddy” Combs — the journals of Kirk Burrowes. These weren't casual notes. Burrowes ran the budgets, coordinated Diddy's travel, saw the money flow, and documented everything from expenses to last-minute car rentals during the exact stretch of time when the East Coast–West Coast tension was at its peak. The documentary connects Burrowes' detailed logs with long-standing witness statements from Duane “Keffe D” Davis, former LAPD detective Greg Kading, and insiders who've talked for decades about Diddy's fear, jealousy, power plays, and connections to people capable of real violence. Nothing is presented as proven fact. But the patterns, the proximity, and the timing create a map — one that's impossible to ignore. We break down the jealousy between Pac, Biggie, and Diddy… the strange travel plans before the Vegas fight… the powerful figures who stood with Diddy in those rooms… the retaliation logic that investigators have discussed for years… and the way Burrowes' journals unintentionally line up with witness claims the public dismissed for decades. This isn't about claiming guilt. It's about understanding the ecosystem of power, fear, and influence that surrounded Diddy in the 90s — and how those same patterns are being raised in today's legal battles. If you want to understand why so many people are suddenly talking, and why investigators and insiders say the “map” now looks very different, this breakdown connects every major piece. Subscribe for more daily deep-dives into the cases shaping American culture — and the shadows behind the headlines. #HiddenKillers #DiddyCase #KirkBurrowes #HipHopHistory #TrueCrimeNews #TupacShakur #BiggieSmalls #MusicIndustry #PopCultureAnalysis #Investigations Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Sean Ross Sapp (@SeanRossSapp) and Alex Pawlowski (@AlexSourGraps) review tonight's episode of AEW Dynamite, December 3, 2025 including: -Samoa Joe & Eddie Kingston Face-To-Face -Kyle Fletcher [3] vs. Kevin Knight [3] in a Continental Classic Gold League Match Kazuchika Okada [0] vs. Pac [3] in a Continental Classic Gold League Match -Jon Moxley [3] vs. Claudio Castagnoli [3] in a Continental Classic Blue League Match -Timeless Love Bombs (Timeless Toni Storm & Mina Shirakawa) vs. Megan Bayne & Marina Shafir in an AEW Women's World Tag Team Championship Tournament Quarterfinal Hardcore Holiday Death Match Save now on the perfect gift with Aura Frames! Get $35 off Carver Mat at https://on.auraframes.com/FIGHTFUL. Use the promo code FIGHTFUL at check out! Grab your EXCLUSIVE NordVPN Deal by going to http://nordvpn.com/fightful to get a Huge Discount off your NordVPN Plan + a Bonus Gift! It's completely risk free with Nord's 30 day money-back guarantee! ➼ https://nordvpn.com/fightful Try it risk-free now with a 30-day money-back guarantee! If you want to bet on Wrestling, or any other sport, check out our new partner where we get ALL of our odds! https://mybookie.website/joinwithFIGHTFUL and use the promo code FIGHTFUL. Deposit $100, get $50. Go in with $200, and they'll make it $100! Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Thirty boxes of handwritten journals. A Bad Boy co-founder who suddenly vanished from the industry. Gang witnesses, investigators, insiders, and a decades-old pattern finally pushed into the light. In today's episode of Hidden Killers, we dig into the most explosive element in the new documentary surrounding Sean “Diddy” Combs — the journals of Kirk Burrowes. These weren't casual notes. Burrowes ran the budgets, coordinated Diddy's travel, saw the money flow, and documented everything from expenses to last-minute car rentals during the exact stretch of time when the East Coast–West Coast tension was at its peak. The documentary connects Burrowes' detailed logs with long-standing witness statements from Duane “Keffe D” Davis, former LAPD detective Greg Kading, and insiders who've talked for decades about Diddy's fear, jealousy, power plays, and connections to people capable of real violence. Nothing is presented as proven fact. But the patterns, the proximity, and the timing create a map — one that's impossible to ignore. We break down the jealousy between Pac, Biggie, and Diddy… the strange travel plans before the Vegas fight… the powerful figures who stood with Diddy in those rooms… the retaliation logic that investigators have discussed for years… and the way Burrowes' journals unintentionally line up with witness claims the public dismissed for decades. This isn't about claiming guilt. It's about understanding the ecosystem of power, fear, and influence that surrounded Diddy in the 90s — and how those same patterns are being raised in today's legal battles. If you want to understand why so many people are suddenly talking, and why investigators and insiders say the “map” now looks very different, this breakdown connects every major piece. Subscribe for more daily deep-dives into the cases shaping American culture — and the shadows behind the headlines. #HiddenKillers #DiddyCase #KirkBurrowes #HipHopHistory #TrueCrimeNews #TupacShakur #BiggieSmalls #MusicIndustry #PopCultureAnalysis #Investigations Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

What's the real cost of fraud, and how do we finally shut the door on the criminals exploiting the transportation industry? In this episode, Chris Burroughs breaks down how the Transportation Intermediaries Association (TIA) is stepping up with a new fraud hotline that connects 2,000 members directly to the FBI, helping track patterns, tighten data collection, and speed up responses to cargo crime! We also dig into how organized crime takes advantage of weak FMCSA oversight, why boosting the broker bond matters, the push for enforcement under MAP-21, the role industry advocacy plays, why unregulated dispatch services are becoming a serious risk, the ongoing broker transparency debate, and the need for consistent standards across the board!   About Chris Burroughs Chris Burroughs is the President and CEO for the Transportation Intermediaries Association (TIA). He brings over 18 years of Congressional affairs experience to TIA. As the former Vice President of Government Affairs for TIA, he led the Government Relations department including the legislative, regulatory, PAC, and internal policy committee functions. Chris served as the staff liaison for the Highway Logistics Conference, the Intermodal Logistics Conference, and several other policy committees within TIA. Chris additionally served on the Board of Directors for the Unified Carrier Registration (UCR) as the Subcommittee Chairman of Industry Advisory Subcommittee and sole representative of the 3PL industry. During his time on Capitol Hill, Chris gained invaluable knowledge of the legislative process. He began his career working on the House Transportation & Infrastructure Committee in 2006 and then later the House Natural Resources Committee. In 2009, Chris joined the Twenty-First Century Group, a bipartisan government affairs firm, as their Director of Government Affairs. In this position, Chris advocated on behalf of multiple clients involved in the transportation, telecommunications, health care, tax, and defense arenas. Additionally, he represented TIA on their issues of interest on Capitol Hill. Chris lives in Gainesville, Virginia with his wife Stacey and children Kelly, Christopher, and Connor. Chris earned a BS degree in Political Science from Shepherd University located in Shepherdstown, West Virginia.  

In this conversation, we pull back the curtain on alpha-gal syndrome diagnostic testing at Thermo Fisher Scientific with Gary Falcetano, PA-C. Gary shares insights into how the alpha-gal syndrome test works and answers some of our most frequently asked questions. How do you talk to your provider about being tested? Is the test covered by insurance? What provider can order the test? He also dives into how Allergy Insider, Thermo Fisher's patient resource, is bringing alpha-gal into the conversation. Tune in now to learn more! Gary Falcetano, PA-C, serves as Senior Manager Global Medical and Scientific Affairs for allergy at Thermo Fisher Scientific. Gary has been a Board Certified Physician Assistant for over 28 years, and is the host of Allergy Insider's ImmunoCAST podcast.Visit Allergy Insider to learn more about their patient resources and be sure to follow on social media: @allergyinsider

What will it take to turn South Africa's municipal crisis around? Can local government still be rescued before the 2026 elections? In this follow-up episode of Democracy Unplugged, moderator Phumi Mashigo brings together panelists from multiple political parties to confront the question head-on. Featuring Afrika Mayibuye Movement's Sydney Baloyi, PAC's Jaki Seroke, GOOD's Sarah Mabotsa and Action SA's Kholofelo Morodi. The Burning Platform

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

Friends, the day of reckoning has finally arrived.We've waited. We've been patient. But tonight, justice will be served. As punishment for his absolute disaster of a performance in the Full Gear predictions game, Tim is finally wearing the Jeff Jarrett shirt on the livestream. You do not want to miss this. We are going to make sure he knows exactly who the “Slapnuts” is tonight.TONIGHT ON THE WRAPUP:Beyond the fashion disaster, we have an incredible episode of AEW Dynamite to break down. The Continental Classic is heating up, and friends are becoming enemies in Fishers, Indiana!The Death Riders Civil War: Jon Moxley vs. Claudio Castagnoli. First time ever in AEW. Both sitting at 3 points. Will they actually fight, or is this part of the master plan?The Rainmaker in Trouble: Kazuchika Okada (0 points!) needs a win desperately against the B*****d PAC. Can Okada get on the board, or is the C2 slipping away?Hardcore Holiday Death Match: Timeless Love Bombs vs. MegaProblems. We love a festive murder match.Joe & Kingston Face-to-Face: The King of Television vs. The Mad King. We expect pure chaos before their title match at Winter is Coming.

Joe Sudbay guest hosts for John. He talks about how amazingly close the Dems got in deep red Tennessee's special election. He also discusses Trump who was visibly drowsy during today's cabinet meeting where the focus was once again on trying to justify extrajudicial military strikes against boats in the Caribbean. Then, he speaks with Richard von Glahn who is the executive director of the People Not Politicians campaign. The group has just 9 days left in a signature drive to bring real opposition to Missouri's latest redistricting scam. Then, Joe talks with Dr. Anahita Dua who is a board certified vascular surgeon and associate professor of surgery based in the Boston area. She's also the Founder and Chair of Healthcare for Action, the nation's largest democratic healthcare PAC! They discuss the latest on the CDC, ACA subsidies and the healthcare landscape as we hit what is predicted to be a monster flu season.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  One day your sales are popping. The next day the dashboard looks frozen.   In this episode, we discuss the actual reasons behind those sudden slowdowns and why most sellers draw incorrect conclusions. If you've felt that 'punch-in-the-gut' moment when everything stops moving, this conversation provides you with perspective, patterns, and a calmer way to read what's going on behind the scenes.   Special guest at the conclusion of today's show, Jeff Schick of JeffSchick.com answers the question: "When is it VERY unsafe to sell textbooks on Amazon?" Use coupon code "JIM" to get your first month of services for only $1 with Jeff and his team!   Watch this episode on our YouTube channel here: https://youtu.be/jUEk2MqKXs   Show note LINKS:   SilentSalesMachine.com - Text the word "free" to 507-800-0090 to get a free copy of Jim's latest book in audio about building multiple income streams online (US only) or visit https://silentjim.com/free11   SilentJim.com/bookacall - Schedule a FREE, customized and insightful consultation with my team or me (Jim) to discuss your e-commerce goals and options.   My Silent Team Facebook group. 100% FREE! https://www.facebook.com/groups/mysilentteam - Join 82,000 + Facebook members from around the world who are using the internet creatively every day to launch and grow multiple income streams through our exciting PROVEN strategies! There's no support community like this one anywhere else in the world!   ProvenAmazonCourse.com - The comprehensive course that contains ALL our Amazon training modules, recorded events and a steady stream of latest cutting edge training including of course the most popular starting point, the REPLENS selling model. The PAC is updated free for life!   SilentJim.com/kickstart - If you want a shortcut to learning all you need to get started then get the Proven Amazon Course and go through Kickstart.   SilentJim.com/thesystem  - (aka as 3P Mercury) - The complete workflow software we created on our team. "The System" automates your Amazon reselling/wholesale business the same way Khang (the creator) automated his $3million reselling business and made it HANDS FREE!            

The Dadley Boyz preview tonight's episode of AEW Dynamite and discuss...Winter Is Coming go-home show!A Hardcore Holiday Death Match!Kazuchika Okada vs. Pac!Someone's 0 has got to go!A Death Riders showdown?!ENJOY!Follow us on Twitter:@AdamWilbourn@MichaelHamflett@MSidgwick@WhatCultureWWEFor more awesome content, check out: whatculture.com/wwe Hosted on Acast. See acast.com/privacy for more information.

A new House report confirms the Biden Administration's coordinated, extralegal "Operation Chokepoint 2.0" to debank the crypto industry. We review the timeline & confirmed shadow debanking conspiracies We discuss the bombshell report from the House Committee on Financial Services that confirms the existence of **Operation Chokepoint 2.0**—a coordinated, extralegal effort by the Biden Administration to push the crypto industry out of the US banking system. Review Nic Carter's original exposes, how the "conspiracy" became formal documentation, and the shift from an existential threat to a clearer path for conducting business in the United States. We also discuss the political "reckoning" ahead for the industry's single-issue campaign spending. Subscribe to the newsletter! https://newsletter.blockspacemedia.com **Notes:** * House report confirms debanking conspiracy. * Extralegal effort to cut crypto banking. * Nick Carter published OCP 2.0 exposes. * Existential risk to US crypto is not near-term. * Crypto actively supported Trump's campaign. * "Single issue PAC" raised biggest money ever. Timestamps: 00:00 Start 01:25 Chokepoint 1.0 04:08 Regulation as maze 07:14 FDIC letter 11:06 Charlie gets de-banked 13:12 Fed letter SR226 -

JaMarcus Shephard's first press conference as Oregon State's head coach has Beaver Nation buzzing. We break down his PAC-12 championship vision, high-energy culture, NIL realities, and what it all means for recruiting, alumni, and fan engagement. From discipline and explosive plays to hope and realistic expectations, we unpack a new era of Beaver football. We also talk donor relations, community involvement, and how OSU can rebuild momentum in a new-look Pac-12.#gobeavs #oregonstate #oregonstatebeavers #oregonstatefootball #jamarcusshephard #headfootballcoach #oregonstatealumni #beavernation #corvallis #osufootball

Chuck is joined by Laura Goble, PA-C to discuss sports specialization by young athletes. In Part 3, they discuss the importance of rest and the risks of exhaustion and overuse. How do we communicate with parents and coaches about the best interest of the athlete? Laura Goble was a speaker at our most recent annual conference. Earn Category 1 CME from this conference and others at PAOS.org!

John Canzano and Jon Wilner talk about Lane Kiffin, the Pac-12, and more. Subscribe to this podcast and share it. • Read John Canzano's work at www.JohnCanzano.com. • Read Jon Wilner's work at www.WilnerHotline.com via the Bay Area News Group. Follow on Twitter: www.Twitter.com/JohnCanzanoBFT www.Twitter.com/WilnerHotline

Welcome to Episode 153 of Wrestling Tonight, powered by G FUEL and Dick Lazers — code TAVERN saves you 20%. Let's get into it. WWE delivered a historic Survivor Series: WarGames from Petco Park — the first outdoor Survivor Series ever, a stadium show under the Netflix/ESPN banner, and John Cena's final Survivor Series appearance. The Men's and Women's WarGames matches brought major spots, shifting alliances, and WrestleMania-season implications, while title bouts like Cena vs. Dominik Mysterio and Stephanie Vaquer vs. Nikki Bella pushed long-term stories forward. From surprise appearances to heel turns, injury updates, and post-show press conference fallout, Survivor Series shaped the next six weeks of WWE television. Meanwhile, the Last Time Is Now tournament is officially down to its final four. After Jey Uso outlasted Rusev and LA Knight put away The Miz — who manipulated his way into the bracket as Sheamus' injury replacement — the semifinals are set: Gunther vs. Solo Sikoa and Jey Uso vs. LA Knight. With Penta removed due to a legitimate shoulder injury and Carmelo Hayes falling to Gunther earlier in the week, the path to Cena's last opponent is clearer than ever. Both semifinals land on December 1 Raw, with the tournament final on December 5 SmackDown — and Cena's final match set for December 13 at Saturday Night's Main Event. AEW's week was no quieter, as the Continental Classic opened with upsets and instant storylines. Kyle Fletcher stunned Kazuchika Okada in the Gold League, Kevin Knight beat Darby Allin, and PAC debuted with a win over Mike Bailey — putting all three atop the standings. In the Blue League, Jon Moxley submitted Mascara Dorada, Claudio Castagnoli powered through Orange Cassidy, and Konosuke Takeshita defeated Roderick Strong to join the early three-point pack. Week 2 arrives with Moxley vs. Claudio, PAC vs. Okada, and Fletcher vs. Knight — plus the Women's World Tag Team Tournament semifinals in a Hardcore Holiday Death Match. Outside the rings, the industry is spinning. Claudio Castagnoli became CMLL World Heavyweight Champion in Mexico City. WWE reportedly made Chris Jericho a retirement storyline offer as his AEW contract nears its end. Andrade is negotiating his non-compete. Rush and Dralistico face surgeries. NXT Gold Rush delivered two major title changes. Seth Rollins outlined his WrestleMania-season comeback timeline. AEW and WWE are juggling schedule shifts, network demands, sponsorship deals, legal battles, backstage politics, injury updates, and new recruits — from high-level athletes entering the Performance Center to departures, surgeries, and reality-era conflicts reshaping locker rooms. And the week ahead is stacked: Moxley vs. Claudio, PAC vs. Okada, an AEW hardcore semifinal, NXT's Iron Survivor summit, The Culling explaining their betrayal, Briggs vs. Heights, TNA Impact fallout, Friday's SmackDown push toward December 13, and a wave of December tent-pole events — ROH Final Battle, NXT Deadline, AEW Winter Is Coming, TNA Final Resolution, AAA Guerra de Titanes, and Cena's farewell match.  

Join Jordan, Commish, Pitt Girl, Beth, and our VP of Podcast Production, Arthur. We recap Week 14 and are joined by special guest Samantha Way, the student sideline reporter for the Wisconsin-Whitewater Warhawks (hey, ULM are the Warhawks too). We discuss Sam's sideline reporting experience from the snowy D3 Playoff game of DePauw & Wisconsin-Whitewater and much more. Then we get into all the snow games of the weekend across all divisions. We avoid all the coaching carousel talk and just recap all of Week 14 but have Marty Smith on standby for imminent coaching talk. We talk about our GOTW, Arkansas State/App State, Bowl-Eligibowls for Georgia Southern/Marshal and Penn State/Rutgers. The Battle on the Bayou and ULM's historic kicking woes, the second leg of the Pac-2 Championship, Florida denies FSU a bowl, Iowa rolls over Nebraska, Miami rolls over Pitt, love on Hawaii and the Tokyo Two, the Snowphers get the AXE, Navy was walking all over Memphis, HAT HAT HAT HAT HAT in the SNOW NW/Illinois, Praise Kent State, CAL and SMU's chaos, MISSOURI STATE AND DELAWARE GET BOWLS!!, Bama sends Delaware to a bowl by forcing an Auburn fumble, THE LOBOS aka THE PEOPLE'S MOUNTAIN WEST CHAMPIONS, Kennesaw's OT win, Diego Pavia for Heisman, the Sickos LSU/OU special, the INSANE YALE comeback, and much, much more!!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"CAT" es sinónimo de maquinaria pesada. Su logo amarillo es uno de los más reconocidos del planeta. Pero esta es también la marca que ves en botas, ropa y hasta teléfonos. La historia de este gigante comienza con una rivalidad encarnizada en el barro de California. A finales del siglo XIX, dos inventores, Benjamin Holt y Daniel Best, competían por dominar el mercado de la maquinaria agrícola. Holt apostaba por la máquina de vapor, pero sus monstruos de 20 toneladas se hundían en el fértil y pantanoso suelo de California. En su desesperación, llegó a construir un tractor con ruedas de 14 metros de ancho. Seguía hundiéndose. La solución llegó en 1904. Holt observó a granjeros poniendo tablones de madera en el barro para avanzar. Inspirado, diseñó un sistema de "pista continua": una cadena de listones de madera. La máquina, por fin, avanzó sobre el lodo. Un fotógrafo de la compañía, al ver el movimiento ondulante, comentó: "se arrastra como una oruga" (crawls like a caterpillar). Holt escuchó la palabra mágica y en 1910 registró la marca "Caterpillar". Pocos años después, esta invención agrícola daría el salto al campo de batalla. En la Primera Guerra Mundial, los ejércitos en Flandes se enfrentaban al mismo problema que Holt: el barro. Un oficial británico, el coronel Ernest Swinton, recordó haber visto un tractor Holt y el ejército británico los importó para mover su artillería pesada. Viendo cómo esas máquinas cruzaban el fango, Swinton tuvo una segunda idea: "¿Y si le ponemos blindaje y armas?". Aunque CAT no construyó el primer tanque, su tractor de orugas fue la inspiración conceptual directa para el Mark I británico. La guerra fue un gran negocio, pero la paz casi los arruina. El mercado se inundó de tractores militares sobrantes. Tanto Holt como su rival, C. L. Best, estaban al borde de la quiebra y endeudados con los mismos bancos. En 1925, los banqueros forzaron un "matrimonio de conveniencia": las dos compañías se fusionaron para crear la Caterpillar Tractor Co. Holt aportó el nombre "Caterpillar"; Best, diseños más modernos. Uno de los aspectos más icónicos de la marca, su color "Amarillo Caterpillar", no llegó hasta 1931. Los primeros tractores eran grises, pintados con pintura militar barata. El amarillo se eligió por una razón pura de seguridad: hacer las máquinas más visibles en las obras al amanecer y al atardecer. La nueva empresa estaba lista para construir el mundo moderno. Las máquinas CAT excavaron la Presa Hoover, los cimientos del Golden Gate y construyeron el sistema de autopistas de EE. UU. Fue aquí donde perfeccionaron el "bulldozer". En la Segunda Guerra Mundial, el bulldozer Caterpillar D8 se convirtió en un arma estratégica. Los "Seabees" (Batallones de Construcción de la Marina) los usaban para desembarcar en las playas del Pacífico y construir pistas de aterrizaje en plena jungla, a veces bajo fuego enemigo. Hoy, Caterpillar es un coloso diversificado. Fabrica los motores diésel que mueven barcos y locomotoras, y camiones mineros del tamaño de una casa. Y su línea de ropa y teléfonos no es casualidad: están pensados para sus clientes. Los teléfonos CAT son indestructibles, diseñados para el bolsillo de un trabajador de la construcción que pasa el día entre el polvo, el agua y el barro.

¡OMAR CRUZ EN LA CASA!

(NOTE regarding this episode: Ben and I both live in semi-remote areas with not the best internet connectivity, and this shows here-and-there in this episode with some audio-oddities. I am very sorry about that, but nevertheless, listeners can contextually understand Ben's points when the hiccup periodically occurs.) Dr. Ben Mattingly along with his wife, Jennifer Mattingly, PA-C, founded and own Wild Med Adventures. He is also the Founder and former Director of the Wilderness Medicine Fellowship Program at Baystate Medical Center, and former Assistant Professor at the University of Massachusetts Medical School's Department of Emergency Medicine.  Ben has a passion for the wilderness and has traveled throughout the world, including a year working in a small ER in New Zealand. With his father he's summited Mt. Ranier, Denali, and Vinson Massif in Antarctica. In 2023, he summited Everest, and completed his goal of tackling the Seven Summits. He has taught wilderness medicine while climbing the highest mountain in Mexico, and in Guatemala, he summited the highest peak in Central America. In addition to mountaineering, Ben rock climbs, scuba dives, backpacks, and is a triathlete, skier, and off-road and extreme sports enthusiast.  He served as the Team Doctor for an American Hockey League team, and has been active in wilderness medicine and medical education throughout his career. Ben was twice awarded the Outstanding Teacher of the Year by his emergency medicine residents, and he has taught wilderness medicine in over 10 countries. Boy, talk about living your life in full, Ben is the poster boy for doing so, and in service of others. We started things off with his origin story, what drew him to medicine, to specialize in emergency medicine, and then subspecialize in wilderness medicine. Don't miss this inspiring and engaging conversation with one of the greats. #wildernessmedicine #emergencymedicine #medicaleducation #entrepreneurship #mountaineering #adventuretravel #alpinism

Mongo and Emily are joined by Adam from Hitting the Turnbuckle to break down the 2025 AEW Continental Classic. We go over the current standings in both the Gold and Blue leagues, including big wins from Kevin Knight, Kyle Fletcher, PAC, Jon Moxley, Claudio Castagnoli, and Konosuke Takeshita. We break down the biggest surprises so far, upcoming matchups like Knight vs Fletcher and Mox vs Claudio, and highlight the breakout stars you need to watch. At the end we had some fun fantasy booking our own C2 with talent from every company and shared why we made our picks. If you want to catch up on all the drama, shockers, and stories in the Continental Classic, this episode has you covered. For a full episode archive (AD FREE) and exclusive content visit CWKPOD.COM  Make sure and follow the show and leave us a 5 Star Frog Splash of a review!  Be sure to Follow us on all of our socials @CruisingwithKayfabe on Facebook and Instagram, @ItsMongo and @CruisingWithKayfabe_Emily on TikTok.  Visit Dubby Energy at https://www.dubby.gg/discount/Mongo?ref=TokPgWhTYa3YrX and use promo code "MONGO" to save 10% on all orders all the time!  Special Thanks to friends of the show the Undone for letting us use their song Miss Fortune! Now available to stream or purchase on Apple, Amazon Music & Spotify.  For more information visit https://wearetheundone.com/ and make sure to give them a follow!

Some fight action in England and California and a world champ readying to move up and fight for antother world title in another weight division joins us on the "Fight Freaks Unite Recap Podcast."Host T.J. Rives returns with insider Dan Rafael of his Fight Freaks Unite Substack and Newsletter are backFirst a recap of the Saturday Matchroom Boxing/DAZN main event at Birmingham, EnglandLight heavyweight Ben Whittaker massive KO1 Benjamin Gavazi. Was this really even a test? What's next for the flamboyant Whittaker? Next we recap Saturday's Boxxer/BBC main event at Derby, England Heavyweight Jeamie “TKV” Tshikeva upsets Frazer Clarke by decision and wins vacant British title. Dan has more.  Plus, a quick recap from the Saturday Manny Pacquiao Promotions ESPN Knock Out bout at Temecula, Calif.Lightweight Manny Pacquiao Jr. Draw  over four rounds with Brendan Lally (both making pro debuts). Not good for Pac-man son's debut.Then, WBC featherweight champion Stephen Fulton is on the Pod as he is moving up to challenge O'Shaquie Foster for his WBC junior lightweight title this Saturday in San Antonio on the PBC on Prime Video PPV undercard of Isaac “Pitbull” Cruz vs. Lamont Roach Jr.Foster-Fulton was originally scheduled on the Octover 25th FUNDORA-THURMAN undercard, but that main event was postponed. So now it's on this show inTexas. And, we have this conversation from earlier.   Some fight news:An update on Teofimo Lopez slated to meet Shakur Stevenson. Dan has the latest on when and where?Zurdo Ramirez's decision to face David Benavidez in May angers Cruiserweight champ Jai Opetaia and his team.And, four division titleholder Kazuto Ioka, who announced in late October that he would move up to bantamweight in pursuit of a title in fifth weight class, will make his debut in at 118 pounds in a WBA title eliminator Maikel Ordosgoitti on Dec. 31 in Tokyo. Dan has the latest.It's all part of the "Fight Freaks Unite Recap Podcast" and make sure to follow/subscribe on Apple/Spreaker/Spotify, etc.! 

Donald Trump anunció un indulto para el expresidente hondureño Juan Orlando Hernández, quien el año pasado comenzó a cumplir una condena de 45 años por conspirar para importar cocaína a Estados Unidos. La noticia resulta sorprendente, ya que el gobierno de Trump continúa endureciendo el asedio contra Venezuela y atacando barcos en aguas internacionales del Caribe y del Pacífico oriental, bajo el argumento de que transportan drogas.El gesto, sin embargo, adquiere sentido en el contexto de las elecciones que se celebran este domingo en Honduras, donde Trump respalda a Tito Asfura, exalcalde y miembro del mismo partido que Hernández, el conservador Partido Nacional. El propio Trump declaró: “Tito y yo vamos a trabajar juntos para luchar contra los narcocomunistas y llevar la ayuda necesaria al pueblo de Honduras”.La paradoja es evidente: ¿por qué hundir barcos en el Caribe mientras se indulta a expresidentes condenados por narcotráfico, en nombre de la lucha contra los llamados “narcocomunistas”? Nos lo cuenta Marta Peirano.Escuchar audio

Cap

Hoy en el podcast comparto algo que tenía muchas ganas de anunciar…Estoy creando una comunidad para meditar en español, un espacio semanal para empezar la semana desde la calma y no desde el ruido.Llevaba tiempo sintiendo que hacía falta un lugar así:un espacio seguro, accesible y suave, donde podamos respirar juntas/os, aterrizar, volver al cuerpo y recordar que no tenemos que hacerlo todo solas/os.Por eso, a partir del 8 de Diciembre, todos los lunes a las 6pm (hora del Pacífico) nos reuniremos por Zoom para una práctica corta y profunda:

"Life isn't just about a 9-5 paycheck and watching Netflix any longer" Just one of many powerful statements from the latest ProvenAmazonCourse.com student we interviewed.   She started with just $600 after buying a confusing course that was offered to her by someone else outside our community. That course lead her to us however, and she's been on a roll ever since!   "I'm quite proud of myself" she says at one point. She should be! She's about to have her first $10,000 month December of 2025!   Hear the full story of her journey as a ProvenAmazonCourse student who is changing her financial future!   Don't forget to check out Sellerboard, our awesome sponsor - THE accurate profit analytics tool for Amazon sellers that helps you calculate your profit precisely accounting for all hidden fees and in real time. Use our link and get a TWO month free trial: https://SilentJim.com/numbers    Watch this episode on our YouTube channel here: https://youtu.be/fd6a0kikEl0   Show note LINKS: The $7 offer that helped Shaundell find us: learning.silentsalesmachine.com/checkouts/ssm/   SilentJim.com/kickstart - If you want a shortcut to learning all you need to get started then get the Proven Amazon Course and go through Kickstart.   SilentJim.com/bookacall - Schedule a FREE, customized and insightful consultation with my team or me (Jim) to discuss your e-commerce goals and options.   ProvenAmazonCourse.com - The comprehensive course that contains ALL our Amazon training modules, recorded events, and a steady stream of the latest cutting-edge training, including of course, the most popular starting point, the REPLENS selling model. The PAC is updated free for life!   https://3pmercury.com/friends The best price on the software that is automating the reselling businesses for 100s of our ProvenAmazonCourse students!   Today's guest: Shaundell Josiah

-Is Texas State head coach G.J. Kinne going to get caught up in the chaotic 2025 college football coaching cycle?-Can the Bobcats beat South Alabama and get to bowl eligibility?-What is the latest on the Pac-12 media deal? -Are you buying or selling Texas State men's basketball after a 6-2 start?Keff Ciardello answers these and more for our regular season finale mailbag.

Patrick Bet-David, Tom Ellsworth and Brandon Aceto are joined by Paul Barron as they break down Campbell's leaked racist recording, Michael Burry's explosive clash with NVIDIA, Google's Gemini 3 crushing ChatGPT, and the rise of a powerful new AI super-PAC heading to Washington.-------

On Tuesday's   Daily Puck Drop, Jason “Puck” Puckett starts off Tuesday's show with headlines covering new injuries to the Seahawks secondary, the Cougars victorious in Maui, trade in MLB, Sheduer Sanders starting gig, and Pro Football Semifinalists announced.  Then, Puck turns his attention to college football and John Canzano from JohnCanzano.comdrops by for his weekly appearance.  They preview Washington vs. Oregon, future of Jedd Fisch, the Big Ten not accepting the Pac-12 schools, the Lane Kiffin mess, Kalen DeBoer and Penn State and breaking news on Oregon State's coaching search and could they get a major assist from the Oregon Ducks??Over to the NFL Puck goes next and he chats with Danny Kelly from The Ringer.  They revisit the Seahawks lackluster win vs. the Titans,  the coaching job of Brian Schottenheimer in Dallas, Pete Carroll's future, Geno Smith flipping off fans, the Seahawks desire for a number two receiver, Sheduer Sanders miserable QBR and Danny hates Thanksgiving food! “On This Day…”  The Kennedy's make multiple appearances, Joe Dimmagio and KING 5 TV! Puck wraps up the show with, “Hey, What the Puck!?”    John Schneider has taken calculated risks last two offseason's and it's paying off. (1:00) Puck (4:43) John Canzano, JohnCanzano.com (41:52) Danny Kelly, The Ringer (1:17:08) “On this Day….”  (1:23:32) “Hey, What the Puck!?” 

The Ringer’s Steven Ruiz stops by to discuss and rank the top NFL quarterbacks, Bump talks about what Quandre could bring to Seattle, they discuss Tre’von Moehrig punching Jauan Jennings in the groin area, whether USC regrets breaking up the PAC 12, and why the Vikings moved on from Sam Darnold.

There's a new software tool that automatically LOCATES and REPORT 1,000s of profitable book flips EVERY DAY! Without ever TOUCHING a book, you could be flipping highly profitable titles every day!   Here's how it works:   The software (there's a paid and free version) scans the 100million books on Amazon constantly and waits for "buying opportunities" and reports them to you automatically.   A buying opportunity is simply when a book is currently being sold on Amazon by someone for far less than it typically and frequently sells for!   You buy low, ship the books to a prep center who then sends them for you to Amazon where they sell for great margins once you know what to look for.   Students of this strategy are seeing incredible results- it's a great "newbie" strategy or simple "add on stream" of income for any experienced Amazon seller. Let's talk about it!   Get details at SilentJim.com/minebooks (use coupon code "JIM" to save $30)   Watch this episode on our YouTube channel here: https://youtu.be/nbMgRdgc0G8   Show note LINKS: SilentJim.com/bookacall - Schedule a FREE, customized and insightful consultation with my team or me (Jim) to discuss your e-commerce goals and options.   ProvenAmazonCourse.com - The comprehensive course that contains ALL our Amazon training modules, recorded events and a steady stream of the latest cutting-edge training, including, of course, the most popular starting point, the REPLENS selling model. The PAC is updated free for life!   Facebook.com/groups/mysilentteam - My Silent Team Facebook group. 100% FREE! Join 82,000+ Facebook members from around the world who use the internet creatively every day to launch and grow multiple income streams through our exciting, proven strategies! There's no support community like this one anywhere else in the world!   Book Mining software: SilentJim.com/minebooks Use coupon code "JIM" to save BIG! To check out the "mini" version, scroll down to the pricing options. You'll see it.

In this powerful and unfiltered part 3 of episode 266, host Mike Ritland sits down with former U.S. Army Green Beret and Afghan-American Kawa Mawlayee — a first-generation immigrant who fled Soviet-occupied Afghanistan as a child, grew up in the American Midwest, and went on to serve 23 years in Special Forces, including multiple combat tours. What starts as a discussion about Trump's leadership style, tariffs, and manufacturing quickly evolves into a raw, no-holds-barred exploration of the biggest issues facing America in 2025: foreign policy hypocrisy, the military-industrial complex, the Israel-Palestine conflict, Islamophobia and the myth of “Sharia law takeover,” America-First nationalism vs. endless overseas entanglements, accountability in leadership, the future of the U.S. military under Pete Hegseth, and whether the country is sliding toward internal conflict. Kawa brings a rare perspective: a Muslim Green Beret who loves America deeply, calls out both parties, refuses PAC money, and isn't afraid to criticize Israel, U.S. foreign policy, or the current administration — all while still serving in the National Guard Special Forces. The result is one of the most honest, nuanced, and at times uncomfortable conversations you'll hear from two combat veterans who actually agree on far more than they disagree. Learn more about your ad choices. Visit podcastchoices.com/adchoices